DiaMedica Therapeutics
DMAC
15 hedge funds and large institutions have $3.91M invested in DiaMedica Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
98% more capital invested
Capital invested by funds: $1.98M → $3.91M (+$1.94M)
1.25% less ownership
Funds ownership: 7.97% → 6.72% (-1.3%)
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$31.1K |
| 2 |
BlackRock
New York
|
+$20K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$18.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.72K |
| 5 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$2.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$184K |
| 2 |
Millennium Management
New York
|
-$118K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$61.1K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$28K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$27K |
DMAC Hedge Fund Activity: Q4 2019 in Review
15 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2019, worth a combined $3.91M — up 98% from $1.98M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DMAC and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was William Blair & Company, opening a new position worth an estimated $31.1K. The largest seller was Wexford Capital, exiting entirely with an estimated $184K sold.
- 15 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2019, down from 17 in Q3 2019.
- Funds reported $3.91M of DiaMedica Therapeutics stock for Q4 2019, up 98% quarter-over-quarter.
- 3 funds opened new DiaMedica Therapeutics positions in Q4 2019 and 5 closed out, a net change of -2 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2019 was William Blair & Company, an estimated $31.1K added.
- The largest DiaMedica Therapeutics seller in Q4 2019 was Wexford Capital, an estimated $184K sold.
Based on aggregated 13F filings for Q4 2019.